Company intelligence / Profile preview

Beijing Defengrei Biotechnology Co. Ltd.

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

BDB-1 (also known as BDB-001) is in Phase II/III development for COVID-19 infections, Phase II for hidradenitis suppurativa, and Phase I/II for ANCA-associated vasculitis. However, some COVID-19 trials have been terminated due to the changing COVID-19 epidemic situation.

Therapeutic areas: DermatologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

BDB-2

Preclinical

Partnerships

InflaRx N.V.Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Beyond the preview

Go deeper on Beijing Defengrei Biotechnology Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Defengrei Biotechnology Co. Ltd..